NCT05147415View on ClinicalTrials.gov

Study of Tesomet With Open-label Extension in Subjects With Hypothalamic Obesity (HO)

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 11, 2021

Primary Completion Date

December 9, 2022

Study Completion Date

December 9, 2022

Conditions
Hypothalamic Obesity
Interventions
OTHER

Placebo

Inactive comparator

DRUG

Tesomet

Fixed-dose combination

Trial Locations (1)

48912

Sparrow Clinical Research Institute, Lansing

Sponsors

Lead Sponsor

Saniona
All Listed Sponsors
lead

Saniona

INDUSTRY

NCT05147415 - Study of Tesomet With Open-label Extension in Subjects With Hypothalamic Obesity (HO) | Biotech Hunter | Biotech Hunter